

We Claim:

1. Use of an anti-CD19 antibody in the manufacture of a medicament for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or small lymphocytic lymphoma, wherein the medicament is to be administered in combination with venetoclax, wherein the anti-CD19 antibody is to be administered at least 7 days prior to the first administration of venetoclax, and wherein the anti-CD19 antibody comprises an HCDR1 region comprising sequence SYVMH (SEQ ID NO:1), an HCDR2 region comprising sequence NPYNDG (SEQ ID NO:2), an HCDR3 region comprising sequence GTYYYGTRVFDY (SEQ ID NO:3), an LCDR1 region comprising sequence RSSKSLQNVNGNTYLY (SEQ ID NO:4), an LCDR2 region comprising sequence RMSNLNS (SEQ ID NO:5), and an LCDR3 region comprising sequence MQHLEYPIT (SEQ ID NO:6).
2. The use according to claim 1, wherein the anti-CD19 antibody is to be administered weekly, bi-weekly or monthly after a first administration on Day 1 and wherein venetoclax is to be administered for the first time on Day 8.
3. The use according to any one of the preceding claims, wherein the anti-CD19 antibody after a first administration on Day 1 is to be administered weekly for the first 3 months.
4. The use according to claim 3, wherein the anti-CD19 antibody after a first administration on Day 1 is to be administered weekly for the first 3 months and bi-weekly for at least the next 3 months.
5. The use according to claim 4, wherein the anti-CD19 antibody after a first administration on Day 1 is to be administered weekly for the first 3 months, bi-weekly for the next 3 months and monthly thereafter.
6. The use according to any one of the preceding claims, wherein an additional dosage of the anti-CD19 antibody is to be administered on Day 4.

7. The use according to any one of the preceding claims, wherein venetoclax is to be administered for the first time on Day 8 with a starting dose of 20mg followed by a weekly ramp-up dosing of 50mg, 100mg, 200mg and 400mg, optionally followed by a daily dosing of 400mg.

8. The use according to any one of the preceding claims, wherein said anti-CD19 antibody and venetoclax are to be administered separately.

9. The use according to any one of the preceding claims, wherein the anti-CD19 antibody comprises a variable heavy chain comprising the sequence
 EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGT
 KYNEKFQGRVTISSDKSISTAYMELSSLRSEDAMYYCARGTYYYGTRVFDYWGQGT
 LTVSS (SEQ ID NO: 10)
 and a variable light chain of the sequence
 DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNL
 NSGVPDRFSGSGSGTEFTLTISSELPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID
 NO: 11).

10. The use according to any one of the preceding claims, wherein the anti-CD19 antibody comprises a heavy chain constant domain comprising the sequence
 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG
 PDVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQF
 NSTFRVVSVLTVVHQDWLNGKEYKCKVSNKALPAAPEEKTISKTKGQPREPQVYTLPPSR
 EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPMLDSDGSFFLYSKLTVDK
 SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 12).

11. The use according to any one of the preceding claims, wherein the anti-CD19 antibody comprises a light chain constant domain comprising the sequence

RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ
DSKD STYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC. (SEQ ID NO:
13).

12. The use according to any one of the preceding claims, wherein the anti-CD19 antibody is to be administered in a concentration of 12 mg/kg.

13. The use according to any one of the preceding claims for treating non-Hodgkin's lymphoma.

14. The use according to claim 13, wherein the non-Hodgkin's lymphoma is follicular lymphoma.

15. The use according to claim 13, wherein the non-Hodgkin's lymphoma is mucosa-associated lymphoid tissue lymphoma.

16. The use according to claim 13, wherein the non-Hodgkin's lymphoma is marginal zone lymphoma.

17. The use according to claim 13, wherein the non-Hodgkin's lymphoma is diffuse large B cell lymphoma.

18. The use according to claim 13, wherein the non-Hodgkin's lymphoma is Burkitt's lymphoma.

19. The use according to claim 13, wherein the non-Hodgkin's lymphoma is mantle cell lymphoma.

20. The use according to any one of claims 1 to 12 for treating chronic lymphocytic leukemia.

21. The use according to any one of claims 1 to 12 for treating small lymphocytic lymphoma.